ACAD Company Financial Information

Symbol Info
ACADIA Pharmaceuticals Inc. (ACAD)
Listed Symbol	ACAD
Name	ACADIA Pharmaceuticals Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share	$-
Latest Fiscal Date	2018-12-31
Latest Fiscal Revenue	$223,807,000
Latest Fiscal EPS	$-1.95
Price Info
21 Day Moving Average	$39.5286
21 Day EMA	$38.100090
50 Day Moving Average	$33.9148
50 Day EMA	$34.826870
200 Day EMA	$28.115720
200 Day Moving Average	26.796000
52 Week High	$44.85
52 Week Low	$14.01
52 Week Change	$93.044300
Alpha	0.002512
Beta	2.7756
Standard Deviation	0.181736
R2	0.275367
Periods	60
Share Information
10 Day Average Volume	1,714,966
20 Day Average Volume	2,362,682
30 Day Average Volume	3,087,508
50 Day Average Volume	2,302,288
Outstanding Shares	144,487,428
Float Shares	143,929,717
Percent Float	99.61%
Short Interest	-
Short Percent Float	-
Short Interest Ratio	-
Short Date
Holders
Institutions	458
Institute Holdings Date	2019-09-30
Institute Bought Previous 3 Months	4,886,996
Institute Holdings Percent	-
Institute Sold Previous 3 Months	9,155,843
Insider Holdings Date	2019-08-31
Insider Bought Previous 3 Months	-
Insider Holdings Percent	0.40%
Insider Sold Previous 3 Months	4
Insiders Shares Owned	557,711
Price Change
7 Day Price Change	$2.3600006
7 Day Percent Change	6.18%
21 Day Price Change	$-0.2200012
21 Day Percent Change	-0.54%
30 Day Price Change	$-0.8699989
30 Day Percent Change	-2.10%
Month To Date Price Change	$4.5300
Month To Date Percent	12.59%
90 Day Price Change	$13.270000
90 Day Percent Change	48.70%
Quarter To Date	$4.529999
Quarter To Date Percent	12.59%
180 Day Price Change	$14.500000
180 Day Percent Change	55.73%
200 Day Price Change	$14.330000
200 Day Percent Change	54.72%
Year To Date	$24.350000
Year To Date Percent	150.59%
Profile
Description	Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Details
Issue Type	CS
Market Cap	$5,854,630,583
Sec Type	EQS
Auditor	Ernst & Young LLP
Total Shares Outstanding	144,487,428
CEO	Stephen R. Davis
Employees	477
Last Audit	UQ
Classification
CIK	0001070494
Industry	Biotechnology
Sector	Healthcare
NAICS	Pharmaceutical Preparation Manufacturing(325412)
Info
Address	3611 Valley Centre Drive Suite 300 San Diego, CA 92130
Website	http://www.acadia-pharm.com
Facisimile	+1 858 558-2872
Telephone	+1 858 558-2871
Email	ir@acadia-pharm.com
Key Ratios
Profitability
EBIT Margin	-103.5
EBITDA Margin	-102.4
Pre-Tax Profit Margin	-69,599.6
Profit Margin Cont	-
Gross Margin	95.20
Profit Margin TOT	-
Income Statements
Revenue	$205,735,000
Revenue Per Share	$1.4239
Revenue 3 Years	$181.09
Revenue 5 Years	$498.23
Valuation Measures
PE Ratio	-
Enterprise Value	$4,829,369,533
Price To Sales	28.457144
Price To Free Cash	-37.8
PE High Last 5 Years	-
Price To Book	13.9
Price To Cash Flow	-
PE Low Last 5 Years	-
Price To Tangible Book	13.9
Financial Strength
Total Debt To Equity	0.0
Int Coverage	-
Current Ratio	6.8
Leverage Ratio	1.2
Quick Ratio	6.5
Long Term Debt To Capital	0.02
Assets
Receivables Turnover	3.4
Invoice Turnover	3.10
Assets Turnover	0.20
Management Effectiveness
Return Assets	-69.05
Return On Equity	-81.96
Return On Capital	-79.26
Dividends
Dividend 3 Years	$-
Dividend 5 Years	$-
Ex Dividend Date
Dividend Rate	$-
Dividend Yield	-
Payment Type